U.S. markets close in 5 hours 23 minutes

  • S&P 500

    4,310.86
    +13.36 (+0.31%)
     

  • Dow 30

    34,564.73
    +62.22 (+0.18%)
     

  • Nasdaq

    14,522.82
    +18.86 (+0.13%)
     

  • Russell 2000

    2,326.89
    +16.34 (+0.71%)
     

  • Crude Oil

    75.05
    +1.58 (+2.15%)
     

  • Gold

    1,777.60
    +6.00 (+0.34%)
     

  • Silver

    26.21
    +0.02 (+0.06%)
     

  • EUR/USD

    1.1865
    0.0000 (-0.00%)
     

  • 10-Yr Bond

    1.4610
    +0.0180 (+1.25%)
     

  • GBP/USD

    1.3787
    -0.0039 (-0.28%)
     

  • USD/JPY

    111.5440
    +0.4610 (+0.42%)
     

  • BTC-USD

    33,152.08
    -1,401.24 (-4.06%)
     

  • CMC Crypto 200

    817.81
    -26.86 (-3.18%)
     

  • FTSE 100

    7,128.02
    +90.55 (+1.29%)
     

  • Nikkei 225

    28,707.04
    -84.49 (-0.29%)
     

Nature's Bounty® Unveils NEW Stress Comfort Fast-Acting Calm

·2 min read

Leading vitamin brand's latest innovation targets occasional stress with all-new chewable tablet format that delivers delicious watermelon flavor

RONKONKOMA, N.Y., July 1, 2021 /PRNewswire/ -- Many people are feeling stressed now more than ever, with studies showing more than half (55%) of Americans say they're more stressed than they were before the COVID-19 pandemic.1 To address this need, Nature's Bounty®, a leading nutrition brand,2 has launched Stress Comfort Fast-Acting Calm. This new COOLMELTS™ chewable watermelon tablet works quickly to soothe your mind in response to stress* and is the perfect solution for anyone with occasional stress.* Made with a non-GMO formula, this 100% drug-free format is available on Amazon.com right now and coming to a Walmart, CVS and Rite Aid near you this summer.

(PRNewsfoto/The Nature's Bounty Co.)
(PRNewsfoto/The Nature's Bounty Co.)

Chewing a tablet of Nature's Bounty® Stress Comfort Fast Acting Calm is a unique experience for consumers that activates the refreshing watermelon chill flavor and delivers a cooling sensation as the tablet quickly dissolves.

For more information about the new product, check out the company's latest blog post, available here.

About The Bountiful Company
The Bountiful Company is a pure play branded leader in global nutrition, living at the intersection of science and nature. As a manufacturer, marketer and seller of vitamins, minerals, herbal and other specialty supplements, and active nutrition products, we are focused on enhancing the health and wellness of people's lives. The Bountiful Company's portfolio of trusted brands includes Nature's Bounty®, Solgar®, Pure Protein®, Osteo Bi-Flex®, Puritan's Pride®, Sundown®, Body Fortress®, MET-Rx®, Ester-C® and Dr.Organic®. For more information, visit Bountifulcompany.com and follow us on LinkedIn, Facebook and Twitter.

Media Contact:
Meghan Sowa
The Bountiful Company
msowa@bountifulcompany.com

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

1 More than half of Americans say they're more stressed than they were before the Covid-19 pandemic (CNBC, July 2020)

2 To conform to how we talk about Nature's Bounty in the S-1.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/natures-bounty-unveils-new-stress-comfort-fast-acting-calm-301324082.html

SOURCE The Bountiful Company

Recommended Stories

  • This Biotech Stock Is Beating GameStop

    When we think of this year's biggest stock market movers, GameStop probably comes to mind. GameStop soared more than 1,700% in the first few weeks of January. Cassava Sciences (NASDAQ: SAVA) has climbed about 1,120% year to date.

  • 5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now

    Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

  • Jazz's leukemia drug gets approved by the FDA

    Shares of Jazz Pharmaceuticals plc gained 3.5% in premarket trading on Thursday, the day after the Food and Drug Administration said it had approved the company's acute lymphocytic leukemia treatment Rylaze. The therapy is an orphan drug, meaning it affects less than 200,000 people in the U.S. Jazz did not immediately respond to a request about how Rylaze will be priced. The drug is expected to be available later this month. Jazz's stock is up 7.6% so far this year, while the broader S&P 500 is

  • FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits

    The government should reimburse Biogen only for actual production costs while further clinical trials determine whether aducanumab really helps patients

  • Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients

    Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche Holding AG (OTC: RHHBY) and Atea jointly develop AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform. On Day 2, patients receiving AT-527 experienced a 0.7 log10 (80%) greater mean reduction from baseline viral load than placebo. AT-527's antiviral activity was also obs

  • Why Global Blood Therapeutics Moved Higher Wednesday

    The pharmaceutical company, which specializes in therapies to fight sickle cell disease, rose nearly 8% on Wednesday.

  • 3 Top Psychedelic Stocks to Buy Now

    Psychedelics such as LSD and psilocybin (colloquially known as "magic mushrooms") have long been known to have therapeutic effects in alleviating depression and mood disorders. As a result, U.S. lawmakers outlawed most psychedelics under the Controlled Substances Act, classifying them in the same group as heroin. Fast-forward half a century, and the political pressure to suppress hippie culture has largely disappeared -- making researchers, patients, and investors alike far more interested in the medical benefits of psychedelics.

  • Covid update: Concerns over delta variant growing

    Dr. Jennifer Pena of Nurx breaks down the serious concerns arising from the delta variant of Covid-19. 

  • In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC

    Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive data from CRISPR/Cas9 genome editing candidate in transthyretin (ATTR) amyloidosis. Previously, other applications of the CRISPR technology had been limited to ex vivo therapy. Jennifer Doudna, a co-founder of Intellia,

  • Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

    Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish Buy rating to all 10. Compass Pathways plc (NASDAQ: CMPS) Cybin Inc. (OTCQB: CLXPF) Enveric Biosciences Inc. (NASDAQ: ENVB) Field Trip Health Ltd. (OTCQX: FTRPF) Mind Cure Health (OTCQB: MCURF) Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) Mindset Pharma Inc. (OTCQB: MSSTF) Mydecine Innovations Group

  • Delta variant gains ground in U.S., men do worse with COVID-19

    The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. The highly transmissible Delta variant of SARS-CoV-2, first identified in India, has become the most prevalent variant among new COVID-19 cases in the United States, according to California-based genomics company Helix. The company's computer models indicate that Delta now accounts for around 40% of new U.S. cases, Dr. William Lee, vice president of science at Helix, said in a statement provided to Reuters.

  • This Explosive Biotech Is Taking On a Huge New Market

    Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

  • This Biotech Stock Doubled Overnight — And Then Hit A Deep Snag

    Biotech stock Cerevel returned some of its gains Wednesday after a Tuesday sprint on promising test results for a schizophrenia drug.

  • Column: Walmart's low-priced insulin shows what a rational drug market should look like

    Walmart has unveiled a private-label insulin that sells for about a fifth of what similar insulins cost. Can we expect the same for other drugs?

  • Delta variant will 'spread like wildfire' in communities with low vaccination rates, doctor says

    The continued spread of the Delta variant of COVID-19 could pose a serious risk to the U.S., particularly the unvaccinated population.

  • Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data?

    Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?

  • Pinterest bans all weight loss ads

    Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday. The digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index (BMI) or similar indexes. Ads promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not "focus on weight loss."

  • U.K. Warns on Rules; Africa Braces for Worst Week: Virus Update

    (Bloomberg) -- U.K. Prime Minister Boris Johnson warned that “extra precautions” might be needed even after the July 19 date he has said will mark the end of the country’s Covid restrictions.Germany said it may ease travel curbs for the U.K. and Portugal, potentially classifying them as “high incidence” Covid-19 countries, rather than places rife with a variant of concern. Cases in Africa are rising so quickly that the continent will soon face its worst week since the start of the pandemic, with

  • These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday

    You might not have heard of them, but one went up big while the other served up a massive disappointment.

  • California virus cases rising as delta variant spreads

    California broadly reopened its economy barely two weeks ago and since then an especially contagious coronavirus variant has spread among the unvaccinated, a development that has health officials on edge and already has prompted Los Angeles County to strongly recommend everyone resume wearing masks inside. LA County, where a quarter of the state's nearly 40 million people live, recommended Monday that vaccinated residents resume wearing face coverings indoors after detecting that about half of all cases were the delta variant.